undamentalytics Newsletter
Sign in

OS Therapies Inc (OSTX) stock

Add to watchlist

Add holding +

NYSE: OSTX NYSE Biotechnology Next results ~November 16, 2026

OS Therapies Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$4.0

Valuation models combined (2)

Base case. Range ~$1.8–$4.6. Weighted average of 2 models (forward price-to-earnings vs peers, forward price-to-sales vs peers), the forward price-to-earnings vs peers counting double.

Price vs value

No Buy/Hold/Sell rating is issued: limited reported history: available models are shown without a Buy/Hold/Sell rating.

OS Therapies Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds21 adding, 9 cuttingOf 5 active managers that changed their stake, 4 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 16, 2026 (estimated)

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 13% in the quarter to 2026-06-30.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in OS Therapies Inc's latest figures clears our strength thresholds.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 74% and a beta of 1.7 against the S&P 500.
  • Short interest rising. Shares sold short rose 33% in a month to 6.5% of tradable shares.
  • Missing expectations. Earnings per share fell short of the consensus estimate in 3 of the last four quarters.

Latest results

Earnings per share
-$0.20 against an average estimate of -$0.23: beat by 13.0%
Share reaction
+0.5% in the first session after the results on August 19, 2025, against -0.8% for the S&P 500
Next report
November 16, 2026; average EPS estimate -$0.12

OS Therapies' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-7.3%
  • 1 week-5.0%
  • 1 month-29.0%
  • This year-17.9%
  • 1 year-38.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 19, 2025

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Leadership
  3. Announcement
  4. Leadership
  5. Agreement
  6. Agreement
  7. Agreement
  8. Agreement ended

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

OS Therapies Inc valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value OS Therapies Inc as an operating company, with every model that fits that kind of business. Cost of equity 9.2%: the 10-year Treasury yield (4.9%) plus a beta of 0.94 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$4.6 ~$4.1–$8.2 Primary model, counts double
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: no twelve-month earnings or share count in the filings yet
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: no twelve-month earnings or share count in the filings yet
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$1.8 ~$1.8–$6.8 Included, half weight
Combined value Weighted average of the models that apply: the primary model (forward price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$4.0 ~$1.8–$4.6 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare OS Therapies Inc with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 16, 2026, before the open. Analysts expect revenue of $0 and EPS of −$0.12 (range −$0.16 to −$0.10) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.70 +32% — 0%
Next $0.35 +150% $27m 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +8.5% on 90 days ago. In the last 30 days, 2 analysts raised OS Therapies Inc's forecast and 1 cut it.

Consensus EPS forecast OS Therapies Inc, last 90 days
−$1.00 −$0.50 $0.00 $0.50 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.65 Current fiscal year, 60 days ago: −$0.78 Current fiscal year, 30 days ago: −$0.68 Current fiscal year, 7 days ago: −$0.70 Current fiscal year, Now: −$0.70 −$0.70 Next fiscal year, 90 days ago: −$0.22 Next fiscal year, 60 days ago: $0.36 Next fiscal year, 30 days ago: $0.32 Next fiscal year, 7 days ago: $0.35 Next fiscal year, Now: $0.35 $0.35

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.65−$0.22
60 days ago −$0.78$0.36
30 days ago −$0.68$0.32
7 days ago −$0.70$0.35
Now −$0.70$0.35

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.23 −$0.20 +13.0%
Mar 2026 −$0.19 −$0.27 −42.1%
Dec 2025 −$0.14 −$0.41 −192.9%
Sept 2025 −$0.12 −$0.21 −71.4%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

4 analysts, Oct 2026
Buy4100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026134
  2. Sep 2026134
  3. Aug 2026134
  4. Jul 2026134

Counts of recommendations published by analysts covering OS Therapies Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
6.5%
of tradable shares
Days to cover
3.41
at average volume
Short interest, 1 month
+33%
to October 15, 2026
Held by institutions
6%
of shares
Held by insiders
21.1%
of shares
Employees
4
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20252026 to date
Return
OSTX−67%−18%
Industry peers (median)−5%−27%
S&P 500+18%+11%
Months that ended higher
OSTX25%36%
S&P 50075%46%
Largest fall from a high during the year
OSTX−78%−49%
S&P 500−19%−9%

Worst fall since August 1, 2024: 78% from December 27, 2024 to April 10, 2025. Getting back needed a 361% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.15 – $2.24
From 52-week high
−48.7%
vs 50-day average
−26.5%
vs 200-day average
−26.4%
Volatility (1 year)
74%
Beta vs S&P 500
1.70

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
2 up, 3 down
typical move ±7.8%
After a week
3 up, 2 down
typical move ±11.7%
After a month
5 up, 0 down
typical move ±32.1%
Results releasedNext dayS&P 500 next day5 days21 days
August 19, 2025 +0.5% −0.8% +6.9% +1.4%
May 16, 2025 −4.2% +0.7% +1.2% +7.8%
March 31, 2025 −17.9% +1.0% −11.7% +25.3%
November 15, 2024 −6.4% −0.9% −11.3% +114.1%
August 15, 2024 +10.1% +1.9% +27.2% +12.0%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$5.5M
Institutions reporting
29
Shares held vs prior quarter
▼ 0.1%
Positions opened / closed
6 / 6

Top buyers and sellers, Q2 2026: 21 institutions bought and 9 sold ; the biggest buyer was Vanguard Capital Management LLC (+308K shares) and the biggest seller Susquehanna International Group, LLP (−435K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Vanguard Capital Management LLC $1.5M 778K 26.9% ▲ 65.6%
Cm Management, LLC $760,000 400K 13.8% 0.0%
Geode Capital Management, LLC $573,408 302K 10.4% ▲ 7.8%
Howard Financial Services, Ltd. $471,202 248K 8.6% ▲ 1.0%
Blackrock, Inc. $460,710 242K 8.4% ▲ 274.4%
Vanguard Fiduciary Trust Co $330,851 174K 6.0% ▲ 49.3%
State Street Corp $228,190 120K 4.1% ▲ 31.7%
Marshall Wace, LLP $191,216 101K 3.5% New
Hightower Advisors, LLC $162,545 86K 3.0% ▲ 462.8%
Northern Trust Corp $134,552 71K 2.4% ▲ 7.2%
Beacon Pointe Advisors, LLC $118,764 63K 2.2% 0.0%
Bridgeway Capital Management, LLC $85,500 45K 1.6% ▲ 80.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not OS Therapies Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 14, 2025 estimated from the company's past filing pattern, not announced

  • August 19, 2025
  • May 16, 2025
  • March 31, 2025
  • November 15, 2024
  • August 15, 2024

Recent SEC filings

Data status

When each part of this page on OS Therapies Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

OS Therapies Inc in brief

What does OS Therapies Inc do?
OS Therapies Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is OS Therapies Inc's stock ticker?
OS Therapies Inc trades under the ticker OSTX on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are OS Therapies Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Vanguard Capital Management LLC, Cm Management, LLC and Geode Capital Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
When is OS Therapies Inc's next earnings date?
Around November 16, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — OS Therapies Inc announces its own schedule.